Drugs / XTR004
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT07187895 | Dec 2024 → Mar 2025 | coronary artery disorder | Sinotau Pharmaceutical Group | Terminated | No outcome recorded |
| Phase 2 | NCT05885841 | Feb 2022 → May 2023 | coronary artery disorder | Sinotau Pharmaceutical Group | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07439133 | Nov 2025 → Jun 2027 expected | coronary artery disorder | Sinotau Pharmaceutical Group | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-11-25 | Sinotau Pharmaceutical Group | XTR004 中国III期临床试验完成首批受试者入组及给药 sinotau.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XTR004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05885841 ↗ |
| Modality | Diagnostic / imaging agent | “myocardial perfusion PET imaging tracer” NCT05885841 ↗ |
| Route | Intravenous | “IV bolus injection of XTR004” NCT05885841 ↗ |